In 1960, FDA approval of the first hormonal contraceptive—more commonly known as “the pill”—revolutionized sexual and reproductive health, giving women unprecedented control over their fertility for the first time in history. Today, there are a range of contraceptive products available to women across the globe. Of the over 30 MPTs in the product development pipeline, 18 have a contraceptive component combined with protection against select sexually transmitted infections (STIs), including HIV, herpes simplex virus (HSV), and chlamydia. Still, women around the world need more choices. As a woman’s needs change and evolve over her lifespan, having a suite of product options for protection against unplanned pregnancy, HIV, and other STIs remains critical.
The IMPT is the first & only initiative dedicated to advancing the field of multipurpose prevention technologies (MPTs), products that combine HIV prevention, other STI prevention, and contraception.
IMPT Secretariat 1750 Howe Avenue, Suite 550 Sacramento, CA 95825 IMPT@cami-health.org
This project is made possible by the generous support of the American people through the United States Agency for International Development (USAID) under the terms of Cooperative Agreement #AID-OAA-A-16-00045. The contents are the responsibility of the IMPT, CAMI Health, PHI, and its partners and do not necessarily reflect the views of USAID or the U.S. Government.
